Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0234
EDITORIAL
|
Overcoming resistance to cetuximab or panitumumab in KRAS wild-type colorectal cancer. |
Prof. Claus-Henning Köhne, PhD.
|
Affiliation: Department of Hematology and Oncology, Onkologie Klinikum Oldenburg, 26133 Oldenburg, Germany.
E-mail: Onkologie@klinikum-oldenburg.de
|
Abstract
Two studies published in the June 28 issue of Nature reveal emergence driver mutations in KRAS undetectable in primary mutation testing as the main cause of resistance to epidermal growth factor receptor (EGFR) blockade with monoclonal antibodies in wild-type KRAS colorectal cancer patients [1,2]. The authors propose early detection of KRAS mutant clones months before clinical evidence of disease progression in the blood circulation as a marker of high risk for subsequent resistance and development of a MEK inhibitor as a rational strategy for overcoming cetuximab or panitumumab resistance . Here, I discuss these exciting perspectives bur also a series of questions and challenges such as the disappointing results of two phase 3 randomized controlled trials [3,4 ] suggesting not only acquired but also primary resistance to EGFR antibodies in wild-type KRAS colorectal cancer.
(Citation: Gastric & Breast Cancer 2012; 11(3): 131-134)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
